Aminoglycoside antibiotics get a leading position in Chinese market
Aminoglycoside antibiotics belong to a class of antibiotics with amino sugars and amino ring alcohol structure. In the clinical trials, it is used for are treated for systemic infection caused by sensitive aerobic gram-negative bacilli.
In the 1960s to 1970s, it had been widely used. In recent years, because of widely clinical application of cephalosporins and quinolones antibiotics and its more serious ear renal toxicity, the application of aminoglycoside antibiotics gets some restrictions.
But because of the aminoglycoside antibiotics against pseudomonas aeruginosa, klebsiella pneumonia.. coli and other gram-negative bacilli PAE (postantibiotic effect) long, is still used in the treatment of aerobic gram-negative bacilli docetaxel caused serious infections meningitis, respiratory tract, urinary tract, skin and soft tissue, gastrointestinal tract, burns, trauma and bone and joint infections, etc., in the antibiotics market, there is an irreplaceable role.
Aminoglycoside antibiotics in clinical medicine in China in the far-reaching. China's newly revised health insurance directory, including the aminoglycoside antibiotics almost all clinical varieties. Aminoglycoside antibiotics, accounting for all the antibiotics market share of around 3%, and the cephalosporins, penicillins, quinolones, and macrolide antibiotics constitute the main structure of the clinical use of antibiotics. But compared with the strong momentum in the past two years, rising carbapenems, and endless stream of new generation cephalosporins and quinolones irinotecan, aminoglycoside antibiotics obviously a lot less. From the aspect of the growth rate of the amount of hospital medicine, aminoglycoside basic flat growth rate with the amount of antibiotic medication.
Aminoglycoside antibiotics, the drugs share the highest etimicin market share exceeds 80% in 2009. Etimicin is a new generation semi-synthetic aminoglycoside antibiotic, has significant advantages as high efficiency, low toxicity, anti-drug-resistant, belonging to the antibiotics category of countries with independent intellectual property rights of a class of drugs.
Currently, there are 34 production approvals for etimicin. In China, there is just a little number of companies which are able to produce the etimicin. Etimicin ranks second in share of aminoglycoside antibiotic medication. The drug share is 16.14 percent in 2008 with rapid growth of drug amount. In contrast, the share of netilmicin decreased significantly from 24.22 percent in 2005l to 1.53 percent in 2009. Netilmicin has more production enterprises in China. The drug regulatory department has awarded a total of 169 production approvals. Source:http://www.cospcn.com
Article Tags: Aminoglycoside Antibiotics
Source: Free Articles from ArticlesFactory.com
ABOUT THE AUTHOR
MHC INDUSTRIAL CO., LTD is a high-tech enterprise which complements in technology and management. The company is a manufacturer of raw materials for global healthy industry . It specializes in providing stable quality, safe and reliable active substance for pharmaceutical.